Galapagos NV logo

GLPG

Galapagos NV

$36.5

Earnings Summary

Revenue
$136.2Mn
Net Profits
$21.55Mn
Net Profit Margins
15.82%
PE Ratio
417.22

Highlights

Revenue:

Galapagos NV’s revenue jumped 112.17% since last year same period to $136.2Mn in the Q3 2022. On a quarterly growth basis, Galapagos NV has generated -1.02% fall in its revenue since last 3-months.

Net Profits:

Galapagos NV’s net profit jumped 133.36% since last year same period to $21.55Mn in the Q3 2022. On a quarterly growth basis, Galapagos NV has generated 213.28% jump in its net profits since last 3-months.

Net Profit Margins:

Galapagos NV’s net profit margin jumped 115.72% since last year same period to 15.82% in the Q3 2022. On a quarterly growth basis, Galapagos NV has generated 214.44% jump in its net profit margins since last 3-months.

PE Ratio:

Galapagos NV’s price-to-earnings ratio after this Q3 2022 earnings stands at 417.22.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Galapagos NV post its latest quarter earnings

EPS Estimate Current Quarter
-0.68
EPS Estimate Current Year
-0.68

Highlights

EPS Estimate Current Quarter:

Galapagos NV’s earning per share (EPS) estimates for the current quarter stand at -0.68 - a -7.06% fall from last quarter’s estimates.

EPS Estimate Current Year:

Galapagos NV’s earning per share (EPS) estimates for the current year stand at -0.68.

Key Ratios

Key ratios of the Galapagos NV post its Q1 2023 earnings

Earning Per Share (EPS)
0

Highlights

Earning Per Share (EPS):

Galapagos NV’s earning per share (EPS) jumped 100% since last year same period to 0 in the Q1 2023. This indicates that the Galapagos NV has generated 100% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2019-06-30
-0.77
-0.86
-11.69%
2019-03-31
-0.99
-0.89
10.1%
2019-12-31
-0.12
-2.1
-1650%
2019-09-30
4.24
6.03
42.22%

Company Information

Galapagos NV is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action.

Organisation
Galapagos NV
Headquarters
Generaal De Wittelaan L11 A3, Mechelen, Belgium, 2800
Employees
0
Industry
Health Technology
CEO
Paul Stoffels